These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 31079917)

  • 1. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
    Huang J; Cao D; Sha J; Zhu X; Han S
    Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
    Furuta M; Kikuchi H; Shoji T; Takashima Y; Kikuchi E; Kikuchi J; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J
    Cancer Sci; 2019 May; 110(5):1599-1608. PubMed ID: 30874360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of delta-like3 and serum NSE in evaluating chemotherapy response and prognosis in patients with advanced small cell lung carcinoma: An observational study.
    Zhu C; Huang J; Jin X; Zhang C; Zhu C; Lv M; Chen S; Du X; Feng G
    Medicine (Baltimore); 2024 Jun; 103(23):e38487. PubMed ID: 38847733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSE, positively regulated by LINC00657-miR-93-5p axis, promotes small cell lung cancer (SCLC) invasion and epithelial-mesenchymal transition (EMT) process.
    Lu L; Zha Z; Zhang P; Li D; Liu G
    Int J Med Sci; 2021; 18(16):3768-3779. PubMed ID: 34790052
    [No Abstract]   [Full Text] [Related]  

  • 5. MicroRNA-485-5p suppresses the proliferation, migration and invasion of small cell lung cancer cells by targeting flotillin-2.
    Gao F; Wu H; Wang R; Guo Y; Zhang Z; Wang T; Zhang G; Liu C; Liu J
    Bioengineered; 2019 Dec; 10(1):1-12. PubMed ID: 30836864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p.
    Lu W; Zhang H; Niu Y; Wu Y; Sun W; Li H; Kong J; Ding K; Shen HM; Wu H; Xia D; Wu Y
    Mol Cancer; 2017 Jul; 16(1):118. PubMed ID: 28697764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
    Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
    Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
    Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
    Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
    Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
    Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal miR-1228-5p down-regulates DUSP22 to promotes cell proliferation and migration in small cell lung cancer.
    Mu X; Yu C; Zhao Y; Hu X; Wang H; He Y; Wu H
    Life Sci; 2024 Aug; 351():122787. PubMed ID: 38851418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
    Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
    EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
    Sharma SK; Pourat J; Abdel-Atti D; Carlin SD; Piersigilli A; Bankovich AJ; Gardner EE; Hamdy O; Isse K; Bheddah S; Sandoval J; Cunanan KM; Johansen EB; Allaj V; Sisodiya V; Liu D; Zeglis BM; Rudin CM; Dylla SJ; Poirier JT; Lewis JS
    Cancer Res; 2017 Jul; 77(14):3931-3941. PubMed ID: 28487384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The microRNA expression signature of small cell lung cancer: tumor suppressors of miR-27a-5p and miR-34b-3p and their targeted oncogenes.
    Mizuno K; Mataki H; Arai T; Okato A; Kamikawaji K; Kumamoto T; Hiraki T; Hatanaka K; Inoue H; Seki N
    J Hum Genet; 2017 Jul; 62(7):671-678. PubMed ID: 28275243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
    Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
    Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
    Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
    Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
    Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
    Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
    Tanaka K; Isse K; Fujihira T; Takenoyama M; Saunders L; Bheddah S; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Jan; 115():116-120. PubMed ID: 29290251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.